secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-05-21T12:00:10+00:00
Accession:  0001437749-26-017994
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia CardiAMP CMI trial: +179 sec exercise tolerance, 82% fewer angina episodes at EuroPCR
--------------------------------------------------------------------------------

- Open-label cohort results presented at EuroPCR; no treatment-emergent major adverse cardiac events.
- Exercise tolerance improved by avg 179 seconds, sustained over 2-year follow-up.
- Angina episodes reduced by avg 82% by 6 months after treatment.
- All patients had refractory angina despite guideline-directed medical therapy and prior revascularization.
- Data support continued clinical development of autologous cell therapy for chronic myocardial ischemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926017994/0001437749-26-017994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926017994/bcda20260520_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer